Page 130 - Read Online

Page 6 of 7 Umar et al. Hepatoma Res 2018;4:71 I http://dx.doi.org/10.20517/2394-5079.2018.31

Table 1. Characteristics of patients not achieving SVR12
No. Age Gender PCR (IU/mL) Treatment status Child class
1 66 M 4.2 × 10 6 Naïve C
2 45 M 5 × 10 6 Naïve A
3 50 M 7.4 × 10 5 Experienced B
4 55 F 1 × 10 6 Naïve A
5 35 M 2.2 × 10 6 Naïve A
SVR: sustained virologic response

to non-compliance and affordability issues. Yet still the data are informative enough to establish the
importance of generic drugs in the treatment of hepatitis C.

Overall the generic drugs are safe and efficacious. These drugs are not only cost effective but also
cost saving and in the long run will help in preventing HCV related decompensated liver diseases,
[15]
hepatocellular carcinomas and liver related deaths . Even for patients who are unable to respond to these
drugs, new DAAs and their generics will be available in the near future. The generics for Velpatasvir are
now available in Pakistan as well. The availability of new and new generic drugs will be the most effective
[12]
method in eliminating Hepatitis C from the globe by 2030 .

In conclusions, Generic sofosbuvir and daclatasvir are cheap, safe and efficacious with a SVR12 of about
83.33% amongst genotype 3 patients. These generics will act as a pivot in the eradication of hepatitis C
infection from the developing world.

DECLARATIONS
Authors’ contributions
Conceived the research question, performed literature review, formulated discussion: Umar M
Performed literature review, formulated introduction and discussion, data analysis: Akhter TS
Formulated research methodology and results, data analysis: Sadiq J
Data collection: Saleem S
Data entry: Khokhar S

Availability of data and materials
Departmental data, Center for Liver and Digestive diseases, Holyfamily Hospital, Rawalpindi 46300. Data
sharing can be considered on personal request to the primary author.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.